US Patent

US10835515 — Carboxamide derivative and its diastereomers in stable crystalline form

Method of Use · Assigned to Orion Oyj · Expires 2036-01-28 · 10y remaining

Vulnerability score 45/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects stable crystalline forms of a carboxamide derivative and its diastereomers, which are potent androgen receptor modulators.

USPTO Abstract

The present disclosure relates to solid crystalline forms of Nâ((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)-propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide (I) and the diastereomers thereof, and to methods for preparing such crystalline forms. Compound (I) and the diastereomers thereof are potent androgen receptor (AR) modulators useful as a medicament.

Drugs covered by this patent

Nubeqa (darolutamide) · Bayer

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4210`	—	Nubeqa

Patent Metadata

Patent number: US10835515
Jurisdiction: US
Classification: Method of Use
Expires: 2036-01-28
Drug substance claim: No
Drug product claim: Yes
Assignee: Orion Oyj
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.